Mission Biocapital
AcceleratorActively deployingSan Francisco · Pre-Seed–Seed · 20 people tracked
Investment thesis
Mission BioCapital's Platinum Program provides comprehensive support for early-stage biomedical innovation by combining physical lab infrastructure, capital deployment, professional drug discovery services, legal and accounting expertise, and mentorship from experienced industry leaders. The program targets high-potential biotech entrepreneurs with differentiated science and dedicated teams, offering access to state-of-the-art facilities across 31 incubators in 22 U.S. and European cities, enabling companies to de-risk their pathways and accelerate toward meaningful therapeutic development.
Source: firm website, verified Jul 21, 2026.
Team · 20 people
from the firm's website
A managing general partner in San Francisco who focuses on seed and early-stage biopharmaceutical investments and overall firm management. He founded Mission Bay Capital and created the first technical incubator for the UC system at QB3, with over 40 portfolio investments and a PhD in Biochemistry from UCSF.
A managing general partner in Cambridge who focuses on new investments in life science tools, therapeutics, and drug delivery. Over the past three decades, he has been involved in early-stage company formation and growth, co-led Ampersand Ventures' life sciences franchise, and co-founded LabCentral.
A managing general partner in Cambridge focusing on new therapeutics investments and company creation opportunities. He founded FORMA Therapeutics and previously served as Managing Director for the Novartis Venture Fund and held roles at Array BioPharma.
A partner based in Cambridge who focuses on new therapeutics investments and portfolio company operations. She holds a PhD in Bioengineering from the University of Pennsylvania and previously completed graduate studies in the HHMI Interfaces program.
A partner in Cambridge focused on fund strategy and investor relations with 10+ years of experience accelerating early-stage life science companies. She previously served as VP at the Massachusetts Life Sciences Center designing investment strategy and worked as a licensing professional at MIT's Technology Licensing Office.
A general partner in Cambridge with 20+ years as a serial biotech entrepreneur and physician background. He is co-founder and president of LabCentral and CEO of BioLabs, both operating laboratory co-working spaces for startup companies across multiple geographies.
A biotechnologist and partner based in San Francisco with over 10 years of operational experience in life science companies and engineering. He co-founded Allopartis Biotechnologies, which was acquired by Novozymes in 2013, and holds a PhD in Bioengineering from UC San Francisco and Berkeley.
A general partner in Cambridge and seasoned entrepreneur with deep expertise in therapeutic innovation and drug development. He co-founded Tidal Therapeutics, acquired by Sanofi in 2021, and Torque Therapeutics, and was Chief Scientific Officer at Merrimack Pharmaceuticals where his team advanced five cancer therapeutics into clinical development.
A partner in San Francisco focusing on early-stage biopharmaceutical investments and company operations. His academic work at Harvard Medical School applied genome editing and single-cell sequencing to stem-cell differentiation studies, contributing to Science's 2018 Breakthrough of the Year.
A principal in Cambridge who identifies and evaluates new investment opportunities and provides operational support to portfolio companies. She completed her PhD at Dartmouth researching maternal immunity to prevent neonatal viral infections.
Chief Operations Officer and Chief Compliance Officer in Cambridge responsible for regulatory compliance, vendor relations, IT and cybersecurity, and back-office operations. He spent 30 years in financial services, including 24 years at State Street Corporation.
An investment associate in San Francisco supporting new therapeutics investments. He joined the firm in 2025 and previously worked as an associate at the T1D Fund focused on biotech investments and served in corporate development at Syros Pharmaceuticals.
An investment analyst based in Copenhagen who identifies and evaluates new investment opportunities across Europe. She holds a PhD in Molecular Medicine from EMBL and Heidelberg University Hospital, with prior experience at Sound Bioventures and Health Innovation Capital.
Director of Operations for the San Francisco office managing investment prospects and administrative support. She previously worked at UCSF's Department of Hematology and Oncology as Program Manager for translational research and cancer programs.
Chief Financial Officer in Cambridge responsible for managing tax and legal issues and overseeing financial operations of the funds. She is a CPA and attorney with over 25 years of private equity experience specializing in tax planning and financial reporting.
Director of Operations in Cambridge overseeing administrative functions and firm infrastructure. He joined the organization in 2016 and previously spent over 20 years in a similar role at Ampersand Capital Partners.
An operating partner in Cambridge providing management and operational leadership to portfolio companies. He previously served as President and CEO of Deciphera Pharmaceuticals and Ensemble Therapeutics, and as Senior Vice President for Pfizer's Global R&D division.
Accounting and Operations Associate in Cambridge responsible for fund accounting and cash management. He joined the firm in June 2024 and previously worked as Senior Operations Associate at The Engine Accelerator.
Vice President of Finance in Cambridge managing the firm's financial reporting and fund-related financial operations. She previously worked at HarbourVest Partners managing financial reporting and SSAE 16 control audits.
Venture Operations Associate in Cambridge supporting the diligence team and MBC's Platinum Program operations. She joined the firm in 2024 and previously worked as Senior Analyst at ClearView Healthcare Partners focusing on pharmaceutical pricing and market access.
What they invest in
from 45 of 59 portfolio companiesBiotech ×36Medical Devices ×29Healthtech ×17Deep Tech ×14AI & Machine Learning ×7Consumer ×4Climate Tech ×3Longevity ×3
HQs:United States×24Azerbaijan×1
Investments · 59 tracked
founders shown can be your intro pathArase Therapeutics develops first-in-class oncology therapeutics that target ADP-ribose Hydrolases, novel proteins in cancer stress pathways. The company focuses on developing new cancer treatments for patients with various cancer types.
BiotechMedical Devices
Paul Chang(President, CEO / CSO and Lead Founder)W. Lee Kraus(Scientific Founder)Michael Taylor(Executive Chairman)
March Bioscience is a cell therapy company assembling leading scientists and drug developers to advance cell therapy treatments. The company focuses on developing therapeutics in the cell and gene therapy space.
BiotechMedical Devices
Sarah Hein(CEO, Co-Founder)Maksim Mamonkin(Co-Founder, Chair Scientific Advisory Board)Malcolm Brenner(Co-founder)
AI Proteins designs engineered miniproteins for drug discovery and development in the biopharmaceutical industry. The company uses artificial intelligence to create novel protein-based therapeutics with improved efficacy, safety, and manufacturability compared to naturally evolved proteins.
AI & Machine LearningBiotechDeep Tech
Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration. The company focuses on patients with neurodegenerative conditions and applies genetics, neuroscience, and immunology to advance new treatments.
AI & Machine LearningBiotechHealthtechLongevityMedical Devices
Arnon Rosenthal(Ph.D.)
Alessa Therapeutics develops a proprietary drug-delivery platform for sustained and localized release of therapies to treat early-stage prostate cancer. The company is advancing Enolen, a drug-eluting implant designed to deliver enzalutamide directly to the prostate with fewer systemic side effects than existing treatments.
BiotechHealthtechMedical DevicesSan Carlos, US
Pamela Munster(Founder, Chief Scientific Advisor and Director)
Nobell Foods produces plant-based dairy cheese made from soybean plants engineered to grow casein protein, working with Midwest farmers. The company targets consumers seeking sustainable cheese alternatives that match the taste and melt characteristics of traditional dairy cheese.
Climate TechConsumerFoodTechSan Francisco, US
Magi Richani(Founder/CEO)in
Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
BiotechDeep TechMedical Devices
Avvio Medical develops Microbubble SonoLithotripsy, a minimally invasive outpatient procedure that uses low-intensity ultrasound to break down ureteral stones without requiring general anesthesia or stents. The technology is designed for clinical-stage development and aims to reduce treatment wait times and expand access to stone care in various clinical settings.
Deep TechHealthtechMedical DevicesSan Francisco, US
Arkuda is an independent information platform that provides analysis and reviews of online gaming platforms operating in Azerbaijan, focusing on legal compliance, security protocols, and user protection for gaming platforms like Mostbet.
ConsumerGamingBaku, AZ
Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity. The company is advancing etakafusp alfa, a cis-targeting IL-2 candidate, for solid tumor treatment and applying its platform to oncology and infectious disease indications.
BiotechHealthtechMedical DevicesSan Francisco, US
Bolt Threads was a manufacturer of biomaterials for personal care formulations. The company is no longer operating.
BiotechNew MaterialsFoxboro, US
Caribou Biosciences is a clinical-stage biopharmaceutical company developing CRISPR genome-editing therapies, including off-the-shelf CAR-T cell therapies for hematologic malignancies and armored cell therapies using its Cas12a chRDNA platform. The company licenses foundational CRISPR-Cas9 intellectual property and advances drug candidates for patients with devastating diseases.
BiotechMedical Devices
Jennifer Doudna(Co-founder)Rachel Haurwitz(President and Chief Executive Officer, Co-founder)Martin Jinek(Co-founder)
Cavalry Biosciences is a biopharmaceutical company focused on developing medicines that leverage the body's inherent regenerative and repair mechanisms, particularly in areas of age-related disease and tissue regeneration. The company applies translational biology and drug development expertise across multiple therapeutic areas.
BiotechDeep TechLongevityMedical Devices
Jan van Deursen, PhD(Co-founder, Advisor)Nathaniel (Ned) David, PhD(Co-founder, Chairman)
Circle Pharma develops cancer treatments using macrocycle therapies designed to reduce side effects compared to conventional therapies. The company serves cancer patients and their caregivers globally.
BiotechDigital HealthHealthtechMedical Devices
David J. Earp(President & CEO)Matthew P. Jacobson(Co-founder)
CookieYes is a cookie consent management platform that helps businesses comply with global data privacy regulations including GDPR, CPRA, and LGPD. The company provides solutions across WordPress, web applications, and Shopify integrations for website owners and developers.
AdTechEnterprise SoftwareSaaSUnited Kingdom, India
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
BiotechHealthtechMedical Devices
eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company. The company is no longer operating.
BiotechSolana Beach, US
Eikonizo develops small molecule therapeutics targeting neurodegenerative and cardiorenal diseases. The company is focused on creating novel, disease-modifying treatments to improve patient outcomes.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Professor at MGH, Harvard, Martinos Center for Biomedical Imaging
Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
BiotechMedical Devices
Michael Kavanaugh(Founding Advisor)
Epiodyne develops small-molecule opioids designed to optimize therapeutic outcomes, with initial focus on safer pain relief and improved opioid use disorder treatment with reduced addiction and respiratory depression risk. The company uses a platform approach to tune drug candidates across a spectrum from inhibitors to full agonists.
BiotechHealthtechMedical DevicesSan Francisco, US
Douglas Crawford, Ph.D.(CEO)Don Gehlert, Ph.D.(Head of Biology)
Cell Microsystems develops laboratory instruments and platforms for cell engineering, culture, and analysis. The company's product suite includes systems for single-cell isolation, 3D cell culture, tissue dissociation, electrophysiology, and cell counting, serving biotech and pharmaceutical research organizations.
BiotechDeep TechHardware
Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options. The company focuses on addressing unmet medical needs in the rare disease space.
Biotech
Steven Axon(Chief Executive Officer)Hicham Alaoui(Chief Scientific Officer)Rose Marino(Chief Medical Officer)Peter McWilliams(Chief Business Officer)
Immunos Therapeutics develops therapies for immuno-oncology and inflammatory diseases. The company focuses on advancing treatments in cancer immunotherapy and inflammation-related conditions.
BiotechHealthtechMedical Devices
Invenio develops rapid on-site tissue imaging systems combined with AI to improve cancer patient care. The company serves pathologists and oncologists with real-time diagnostic tools for cancer detection.
AI & Machine LearningBiotechDeep TechMedical Devices
Jay Trautman(President & CEO, Co-Founder)Chris Freudiger(Chief Technology Officer, Co-Founder)
Jupiter is a biotech company that discovers and develops new medicines across multiple therapeutic areas. The company is led by a team of experienced scientists and executives with a track record of creating approved drugs and founding successful biotech companies.
BiotechChapel Hill, US
Ned Sharpless(Co-founder & CEO)Leigh Delacy(Co-founder & Partner and COO)
Kit provides email marketing and commerce tools for creators and independent businesses to reach audiences and monetize their work through newsletters and storefronts.
Creator EconomyMarketing TechSaaS
Nathan Barry(Founder + CEO)
LogicInk develops wearable biochemical sensors that detect environmental and personal health signals—such as UV exposure, air quality, and microbiome changes—to provide real-time wellness feedback. The platform allows users to monitor conditions impacting physical and mental health through customizable, worn sensors that integrate daily health awareness with dynamic environmental data.
BiotechConsumerHardwareHealthtechWellness & Fitness
Mammoth Bio develops technology to read and write the code of life, operating in the biotechnology sector.
BiotechDeep TechMedical DevicesBrisbane, US
Jennifer Doudna(Founder)Trevor Martin(Co-founder, Chief Executive Officer)Janice Chen(Co-founder, Chief Scientific Officer & President, Research)Lucas Harrington(Co-founder)
Mediartx develops novel therapies for patients with fibrotic diseases.
BiotechMedical Devices
Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)
Myka Labs develops AI-powered sensor systems and medical devices for minimally invasive surgical repair of congenital birth defects, particularly tracheoesophageal malformations. The company creates sensorized catheters and imaging augmentation technology for pediatric and general surgeons.
AI & Machine LearningDeep TechMedical DevicesSan Francisco, US
Daniel Laser(CEO)Michael Harrison(Founder and Chief Scientific Officer)Lee Swanstrom(Chief Medical Officer)Dan Laser(CEO)
Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves. The company is advancing taplucainium inhalation powder, a first-in-class therapy in Phase 2b clinical development for refractory and unexplained chronic cough, with potential applications in pain, itch, and other conditions driven by neurogenic inflammation.
BiotechHealthtechMedical Devices
RickJim
Nuvig Therapeutics develops immune-modulating medicines for autoimmune diseases by harnessing endogenous regulatory mechanisms to resolve immune dysregulation. The company targets patients with chronic inflammatory and autoimmune conditions.
BiotechHealthtechMedical Devices
PanTher develops targeted cancer therapeutics that deliver drugs directly to tumor sites at high concentrations over extended periods, aiming to improve clinical outcomes while reducing side effects. The platform is designed to be applicable across multiple therapeutic types for oncology treatment.
BiotechMedical Devices
Laura Indolfi(Chief Executive Officer and Co-Founder)
Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells. The company targets the significant unmet need for remyelinating treatments that could repair damage caused by MS and potentially restore lost function.
BiotechDeep TechMedical Devices
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms. The company was founded by neuroscientists from Harvard to translate emerging discoveries about disease pathways into treatment breakthroughs for ALS patients.
BiotechDeep TechMedical DevicesCambridge, US
Kevin Eggan(Co-founder)Roet(Co-founder)Woolf(Co-founder)
Developed site-specific protein conjugation and linker technologies; acquired by Catalent Pharma Solutions in 2014.
Sensorium Therapeutics is a clinical-stage biotech company developing novel CNS therapies for anxiety, epilepsy, and cognitive dysfunction using its SensAI platform, which integrates AI, chemistry, and curated natural product data to identify therapeutic patterns from over 50 million biological relationships.
AI & Machine LearningBiotechDigital Health
ShapeTX develops programmable RNA medicines by combining artificial intelligence with RNA technology to address genetic causes of disease.
AI & Machine LearningBiotechDeep Tech
Josef von Rickenbach, PhD(Co-Founder)
Sound Agriculture develops bio-inspired soil and crop solutions that reduce synthetic fertilizer use and improve nutrient efficiency for growers. The company serves farmers globally, with a focus on climate-friendly agriculture and addressing environmental challenges like water pollution and greenhouse gas emissions from fertilizer loss.
AgTechCleantechClimate TechImpact & Social Good
Eric Davidson, PhD(Founder)Travis Bayer, PhD(Founder)
Symbiome develops skin microbiome-based wellness products that restore ancestral skin health through proprietary fermentation and Amazonian botanical ingredients. The company targets consumers seeking reparative skincare solutions that address modern skin degradation through microbiome restoration.
ConsumerHealthtechWellness & Fitness
Tangible Science develops contact lens solutions designed to improve comfort and durability for wearers and to provide eye care professionals with more effective treatment options. The company serves contact lens wearers, optometrists, ophthalmologists, and lens manufacturers.
HealthtechMedical Devices
<UNKNOWN>
Tune Therapeutics develops a therapeutic platform targeting the epigenome to treat complex diseases and regenerative medicine applications. The company works on novel gene network therapies for challenging diseases.
BiotechDeep TechHealthtechLongevityMedical DevicesDurham and Seattle, US
John McHutchison(CEO, Chairman of the Board)
Terrestrial develops the Tacterra microarray patch platform, a dissolvable skin-patch technology for delivering therapies including GLP-1 without injection. The platform targets patients seeking more convenient, pain-free administration of next-generation therapeutics.
BiotechHealthtechMedical Devices
Rachel Sha(CEO)
Vedere Bio develops optogenetics-based gene therapies for inherited retinal diseases (IRDs) and geographic atrophy (GA), using proprietary AAV vectors for intravitreal administration to restore vision in visually impaired patients globally.
BiotechDeep TechMedical DevicesCambridge, US
Scientific founders at University of California, Berkeley
Vivace Therapeutics is an oncology-focused drug discovery and development company creating small-molecule inhibitors targeting the Hippo-YAP pathway to treat cancers including mesothelioma, meningioma, and various other tumor types. The company adopts a capital-efficient approach to advance novel cancer therapeutics, with potential applications also in fibrotic disease.
BiotechHealthtechMedical DevicesSan Mateo, US
<UNKNOWN>
Wildtype grows salmon directly from fish cells using cellular agriculture, allowing production of seafood without wild-caught or farmed fish. The company serves restaurants and consumers seeking sustainable seafood with reduced contaminants.
BiotechClimate TechFoodTech
Board seats · per SEC filings · 7
what is this? ⓘ$40M raise · filed Apr 2026 · via Ulrik B. Nielsen
$75.7M raise · filed Dec 2025 · via Cassidy Blundell
$24.9M raise · filed Sep 2025 · via Johannes C.D. Fruehauf
$31.6M raise · filed May 2025 · via Douglas Crawford, Steve Tregay
$68.6M raise · filed May 2024 · via Cassidy Blundell
$10.2M raise · filed Jun 2022 · via Robert G. Blazej
$2M raise · filed Mar 2021 · via Johannes Fruehauf
Inferred from directors named on each company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Frequently asked questions
- What stage does Mission Biocapital invest at?
- Mission Biocapital invests at the Pre-Seed, Seed stages.
- What is Mission Biocapital's typical check size?
- Mission Biocapital typically writes checks of $500K – $500K.
- What sectors does Mission Biocapital focus on?
- Mission Biocapital focuses on Biotech, Deep Tech, Digital Health, Medical Devices.
- Where is Mission Biocapital located?
- Mission Biocapital is headquartered in San Francisco, US.
Images
Similar investors
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
Innovestor is a Finnish investment manager that operates across venture capital, real estate, and energy storage sectors. The firm invests in early-stage technology and life science startups, energy-efficient commercial real estate, and battery storage and solar solutions. Innovestor also provides corporate venturing advisory services.
An early-stage venture capital firm investing in technology founders building solutions across multiple sectors.
Apple Tree Partners is a life sciences venture capital firm that creates and builds transformative biotechnology companies from early-stage science through public markets. The firm works with scientists at various stages, from pre-IP ideas to company spinouts, providing capital, strategic guidance, and operational resources.
SV Tech Ventures is a Palo Alto-based venture capital firm investing in early-stage technology startups with significant growth potential. The firm supports portfolio companies through business strategy, product development, fundraising, and talent acquisition, leveraging an extensive network of industry contacts.